Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model

Full text
Author(s):
Trindade-da-Silva, Carlos A. [1] ; Clemente-Napimoga, Juliana T. [1] ; Abdalla, Henrique B. [1] ; Rosa, Sergio Marcolino [1] ; Ueira-Vieira, Carlos [2] ; Morisseau, Christophe [3] ; Verri Jr, Waldiceu A. ; Martins Montalli, Victor Angelo [1] ; Hammock, Bruce D. [3, 4] ; Napimoga, Marcelo H. [1]
Total Authors: 10
Affiliation:
[1] Inst Sao Leopoldo Mandic, Fac Sao Leopoldo Mandic, Lab Neuroimmune Interface Pain Res, R Jose Rocha Junqueira 13, BR-13045755 Campinas, SP - Brazil
[2] Univ Fed Uberlandia, Inst Biotechnol, Lab Genet, Uberlandia, MG - Brazil
[3] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Dept Entomol & Hematol, Davis, CA 95616 - USA
[4] EicOsis LLC, Davis, CA - USA
Total Affiliations: 4
Document type: Journal article
Source: FASEB JOURNAL; v. 34, n. 7 MAY 2020.
Web of Science Citations: 0
Abstract

Epoxyeicosatrienoic acids (EET) and related epoxy fatty acids (EpFA) are endogenous anti-inflammatory compounds, which are converted by the soluble epoxide hydrolase (sEH) to dihydroxylethersatrienoic acids (DHETs) with lessened biological effects. Inhibition of sEH is used as a strategy to increase EET levels leading to lower inflammation. Rheumatoid arthritis is a chronic autoimmune disease that leads to destruction of joint tissues. This pathogenesis involves a complex interplay between the immune system, and environmental factors. Here, we investigate the effects of inhibiting sEH with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) on a collagen-induced arthritis model. The treatment with TPPU ameliorates hyperalgesia, edema, and decreases the expression of important pro-inflammatory cytokines of Th1 and Th17 profiles, while increasing Treg cells. Considering the challenges to control RA, this study provides robust data supporting that inhibition of the sEH is a promising target to treat arthritis. (AU)

FAPESP's process: 17/22334-9 - Use of drug delivery systems for the development and application of anti-inflammatory agents with potential immunomodulatory and neuroprotective effects
Grantee:Marcelo Henrique Napimoga
Support Opportunities: Research Projects - Thematic Grants